A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- OBSERVATIONAL
- Evidence population
- Human clinical study registration
- Participants
- 150
- Population
- ALL · 55 Years to 95 Years
- Duration
- 2019-01-02 to 2026-06-01
- Intervention
- Orthoptic assessment (Outcome measure)
- Comparator
- Not reported
- Outcomes measured
- Change in incomplete retinal pigment epithelial and outer retinal atrophy (iRORA) from baseline — Months 0 (baseline),…; Change in Drusen morphology from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48; Change in Subfoveal drusen area from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48; Change in other drusen area from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48; Change in Drusen reflectivity from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48; Change in other Drusen homogeneity from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48; Change in ellipsoid zone disruption from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48; Change in Drusen homogeneity from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48; Change in hyperreflective foci from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48; Change in hyperreflective foci location (within 500-μm disc area) from baseline — Months 0 (baseline), 6, 12, 18, 24, 3…; Change in hyperreflective foci association to drusen from baseline — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and…; Progression to Moderate Vision Loss — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48; Geographic Atrophy (GA) Growth Rate — Months 0 (baseline), 6, 12, 18, 24, 30, 36, 42 and 48; Progression to Advanced AMD according to international classification/grading system — Months 0 (baseline), 6, 12, 18,…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as OBSERVATIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.